Preventing Dangerous Liaisons

  • Author: Melania Tesio
  • Published: 18 June 2013
  • Copyright: Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim
  • Source / Publisher: Nature Communications/Nature Publishing Group
thumbnail image: Preventing Dangerous Liaisons

The growth of advanced prostate cancer depends on the androgen receptor (AR). Following binding to the male hormone testosterone and to its metabolite 5α-dihydrotestosterone, AR interacts with its cofactor PELP1 (proline, glutamic acid, and leucin protein 1). By this it promots the transcription of genes involved in cellular proliferation.

Preethi Ravindranathan, University of Texas Southwestern Medical Center at Dallas, USA, and colleagues designed a peptidomimetic – a small protein-like chain designed to mimic a peptide – that blocks AR activation by preventing its binding to PELP1. This novel molecule called D2 (pictured) acts by mimicking the LXXLL motif, a PELP1 sequence which is crucial for its binding to AR.

When tested in an animal model, D2 blocked the androgen-dependent growth of prostate tumors. This compound may, therefore, constitute a novel pharmacological tool to treat advanced prostate cancers.

Article Views: 3127

Sign in Area

Please sign in below

Additional Sign In options

Please note that to comment on an article you must be registered and logged in.
Registration is for free, you may already be registered to receive, e.g., the newsletter. When you register on this website, please ensure you view our terms and conditions. All comments are subject to moderation.

Article Comments - To add a comment please sign in

If you would like to reuse any content, in print or online, from, please contact us first for permission and consult our permission guidance prior to making your request

Follow on Facebook Follow on Twitter Follow on YouTube Follow on LinkedIn Follow on Instagram RSS Sign up for newsletters

Magazine of Chemistry Europe (16 European Chemical Societies) published by Wiley-VCH